Solange Peters, MD, PhD, Highlights Practicing Changing Research From the 2021 ESMO Annual Congress
Solange Peters, MD, PhD, detailed several important abstracts from the Presidential Symposia at the 2021 ESMO Congress she believes will be practice changing.
CancerNetwork spoke with Solange Peters, MD, PhD, head of the medical oncology service and chair of thoracic oncology in the Oncology Department at the Centre Hospitalier Universitaire Vaudois and president of the European Society for Medical Oncology (ESMO), about some of the potentially practice changing abstracts that were presented during the2021 European Society of Medical Oncology Congress. Peters highlight the importance of the phase 3 IMpower010 trial (NCT02486718), which examined the use of adjuvant atezolizumab (Tecentriq) in patients with non–small cell lung cancer, as well as the phase 2 FIRSTMAPP trial, which examined the use of sunitinib (Sutent) in pheochromocytoma and paraganglioma compared with placebo.
Transcription:
After tomorrow, we have the additional detailed presentation about adjuvant atezolizumab in lung cancer in IMpower010.1 It has been previously presented, but it's good because this presentation will tell us who the are patients who have to receive adjuvant atezolizumab; [it will] really go into the subgroups. We also have an amazing trial, which is the first randomized trial in a super rare disease entity, which is malignant progressive pheochromocytoma and paraganglioma, which [was treated with] sunitinib versus placebo.2 [It’s] really amazing to do a trial in such a rare entity. We [also] have 2 abstracts about SARS-CoV-2 immunity—1 about the vaccine and 1 about immunity—on Monday, which are very important for our patient community. All of these abstracts, altogether 11 abstracts through 3 presidential symposia, will change the practice.
References
- Felip E, et al. IMpower010: Patterns of relapse and subsequent therapy from a Phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in stage IB-IIIA non-small cell lung cancer (NSCLC). Presented at: 2021 ESMO Congress; September 16-21, 2021; virtual. Abstract LBA9.
- Baudin E, Goichot B, Berruti A, et al. First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): An academic double-blind trial investigating sunitinib. Annals of Oncology. 2021;32(suppl_5): S621-S625. doi:10.1016/annonc/annonc700.
Synovial Fluid in Checkpoint Inhibitor–Induced Inflammatory Arthritis
This case report and literature review emphasize that ICI-IA should not be ruled out based on the presence of synovial fluid with elevated WBC with a neutrophil predominance. Early steroid use should be considered.
